Antiparkinsons

ANTIPARKINSONIAN AGENTS MA. LENY ALDA G. JUSAYAN, MD DEPARTMENT OF PHARMACOLOGY

PARKINSONISM ,[object Object],[object Object],[object Object],[object Object],[object Object]

The UK Parkinson's Disease Society Brain Bank Criteria For Clinical Diagnosis: ,[object Object],[object Object],[object Object]

Motor Symptoms: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Nonmotor Symptoms: ,[object Object],[object Object],[object Object],[object Object]

What causes Parkinson’s Disease? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PATHOGENESIS: ,[object Object],[object Object],[object Object],[object Object],[object Object]

MOTOR SYMPTOMS: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CHOREA ,[object Object],[object Object],[object Object]

TICS ,[object Object],[object Object],[object Object],[object Object]

ATHETOSIS ,[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object]

WHAT CAN BE DONE TO HELP PARKINSON’S SUFFERERS?

GOALS OF TREATMENT: ,[object Object],[object Object]

PATHOPHYSIOLOGIC BASIS OF TREATMENT: ,[object Object]

CASE 2 ,[object Object],[object Object],[object Object]

REMEDIES FOR STEP 1: DOPAMINE REPLACEMENT

LEVODOPA ,[object Object],[object Object],[object Object],[object Object],[object Object]

PHARMACOKINETICS: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CLINICAL USE: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ADVERSE EFFECTS: ,[object Object],[object Object]

ADVERSE EFFECTS: ,[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object]

DRUG INTERACTIONS: ,[object Object],[object Object],[object Object],[object Object]

CONTRAINDICATIONS: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CASE 3 ,[object Object],[object Object]

PERIPHERAL DOPAMINE DECARBOXYLASE INHIBITORS (PDI) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CASE 4 ,[object Object],[object Object]

DOPAMINE AGONISTS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ERGOT ALKALOIDS: ,[object Object],[object Object],[object Object],[object Object],[object Object]

ERGOT ALKALOID: ,[object Object],[object Object],[object Object],[object Object]

NON-ERGOT DOPAMINE AGONISTS: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

NON-ERGOT ALKALOIDS: ,[object Object],[object Object],[object Object]

ADVERSE EFFECTS: ,[object Object],[object Object],[object Object],[object Object],[object Object]

CONTRAINDICATIONS: ,[object Object],[object Object],[object Object],[object Object]

APOMORPHINE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

MONOAMINE OXIDASE INHIBITORS ,[object Object],[object Object]

SELEGILINE ( Deprenyl) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SELEGELINE ,[object Object],[object Object],[object Object],[object Object],[object Object]

DRUG INTERACTION: ,[object Object]

RASAGILINE ,[object Object],[object Object],[object Object]

CATHECO-O-METHYLTRANSFERASE INHIBITORS: ,[object Object],[object Object],[object Object]

CATHECOL-O-METHYLTRANSFERASE INHIBITORS: ( SELECTIVE) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

STALEVO ,[object Object],[object Object],[object Object]

SIDE EFFECTS: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

AMANTADINE ,[object Object],[object Object],[object Object],[object Object],[object Object]

CLINICAL USE: ,[object Object],[object Object],[object Object],[object Object],[object Object]

CONTRAINDICATIONS: ,[object Object],[object Object]

ACETYLCHOLINE BLOCKING AGENTS: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CONTRAINDICATIONS: ,[object Object],[object Object],[object Object]

SURGICAL PROCEDURES: ,[object Object],[object Object]

NEURONAL DEATH ,[object Object],[object Object],[object Object],[object Object]

NEURONAL DEATH ,[object Object],[object Object]

ISCHAEMIC BRAIN DAMAGE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CLINICAL SCENARIO ,[object Object]

ALZHEIMER’S DISEASE ,[object Object],[object Object],[object Object],[object Object],[object Object]

MOLECULAR MODEL FOR THE DEVELOPMENT OF ALZHEIMERS DISEASE

PATHOPHYSIOLOGY: ,[object Object],[object Object],[object Object],[object Object],[object Object]

PATHOPHYSIOLOGY: ,[object Object],[object Object]

AMYLOID PLAQUES ,[object Object]

NEUROFIBRILLARY TANGLES: ,[object Object],[object Object]

DRUGS FOR ALZHEIMER’S DISEASE

CHOLINESTERASE INHIBITORS: ,[object Object],[object Object],[object Object],[object Object],[object Object]

TACRINE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DONAZEPIL, RIVASTIGMINE, GALANTAMINE ,[object Object],[object Object]

ADVERSE EFFECTS: ,[object Object],[object Object],[object Object]

NEURONAL NICOTINIC RECEPTORS (NNRs)

TARGACEPT ,[object Object],[object Object],[object Object]

[object Object],[object Object]

NMDA GLUTAMATE RECEPTOR INHIBITORS

MEMANTINE (Ebixa) ,[object Object],[object Object],[object Object],[object Object]

TREATMENT: ,[object Object],[object Object],[object Object],[object Object],[object Object]

POST –TEST: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Antiparkinsons

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (6)

Similar to Antiparkinsons

Similar to Antiparkinsons (20)

More from MD Specialclass

More from MD Specialclass (20)

Recently uploaded

Recently uploaded (20)

Antiparkinsons